Antibodies

Patent metadata

Field	Value
Publication number	US-11008399-B2
Application number	US-202017077376-A
Country	US
Kind code	B2
Filing date	Oct 22, 2020
Priority date	Mar 12, 2018
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

First claim

The invention claimed is:

1. An antibody which binds to human 5T4 and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 41, 42, and 43, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 45, the sequence DAS, and SEQ ID NO: 46, respectively.

2. The antibody according to claim 1 , which comprises a VH region comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 40 and a VL region comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 44.

3. The antibody of claim 1 , which comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 40 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 44.

4. The antibody of claim 1 , which is a monoclonal antibody.

5. The antibody of claim 1 , which is a full length antibody.

6. The antibody of claim 1 , which comprises a human IgG1 constant region.

7. The antibody of claim 1 , which comprises a kappa light chain constant region or lambda light chain constant region.

8. A bispecific antibody comprising a first heavy chain and a first light chain comprising a first antigen-binding region corresponding to the antigen-binding region of the antibody of claim 1 , and a second heavy chain and a second light chain comprising a second antigen-binding region.

9. A bispecific antibody comprising a first heavy chain and a first light chain comprising a first antigen-binding region corresponding to the antigen-binding region of the antibody of claim 2 , and a second heavy chain and a second light chain comprising a second antigen-binding region.

10. A bispecific antibody comprising a first heavy chain and a first light chain comprising a first antigen-binding region corresponding to the antigen-binding region of the antibody of claim 3 , and a second heavy chain and a second light chain comprising a second antigen-binding region.

11. The bispecific antibody of claim 8 , wherein the second antigen-binding region binds to human CD3.

12. The bispecific antibody of claim 11 , wherein the second antigen-binding region comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 54, 55 and 67, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 58, the sequence GTN, and SEQ ID NO: 59, respectively.

13. The bispecific antibody of claim 12 , wherein the second antigen-binding region comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 68 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 60.

14. The bispecific antibody of claim 11 , wherein the first antigen-binding region comprises a VH region comprising the amino acid sequence of SEQ ID NO: 40 and a VL region comprising the amino acid sequence of SEQ ID NO: 44, and the second antigen-binding region comprises a VH region comprising the amino acid sequence of SEQ ID NO: 68 and a VL region comprising the amino acid sequence of SEQ ID NO: 60.

15. The bispecific antibody of claim 14 , which is a full length antibody.

16. The bispecific antibody of claim 15 , which comprises a human IgG1 constant region.

17. A bispecific antibody comprising a first heavy chain and a first light chain comprising a first antigen-binding region which binds to human 5T4, and a second heavy chain and a second light chain comprising a second antigen-binding region which binds to human CD3, wherein:
(a) the first antigen-binding region comprises a variable heavy chain (VH) region comprising the amino acid sequence set forth in SEQ ID NO: 40 and a variable light chain (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 44, and
(b) the second antigen-binding region comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 68 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 60,
wherein the bispecific antibody comprises a human IgG1 Fc region, and wherein the first heavy chain comprises a constant region wherein the amino acid residues corresponding to L234, L235, D265 and F405 in a human IgG1 heavy chain according to EU numbering are F, E, A and L, respectively, and the second heavy chain comprises a constant region wherein the amino acid residues corresponding to L234, L235, D265 and K409 in a human IgG1 heavy chain according to EU numbering are F, E, A and R, respectively, and
wherein the first light chain and second light chain comprise light chain constant regions comprising the amino acid sequences set forth in SEQ ID NOs: 95 and 96, respectively.

18. The bispecific antibody of claim 17 , which comprises a Fab-arm of a first monoclonal antibody which binds to human 5T4, and a Fab-arm of a second monoclonal antibody which binds to human CD3, wherein the Fab-arm of the first monoclonal antibody comprises the first heavy chain and the first light chain of the bispecific antibody, and wherein the Fab-arm of the second monoclonal antibody comprises the second heavy chain and the second light chain of the bispecific antibody.

19. A bispecific antibody comprising a first heavy chain and a first light chain comprising a first antigen-binding region which binds to human 5T4, and a second heavy chain and a second light chain comprising a second antigen-binding region which binds to human CD3, wherein:
(a) the first antigen-binding region comprises a variable heavy chain (VH) region comprising the amino acid sequence set forth in SEQ ID NO: 40 and a variable light chain (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 44, and
(b) the second antigen-binding region comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 68 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 60,
wherein the bispecific antibody comprises a human IgG1 Fc region, and wherein the first heavy chain comprises a constant region wherein the amino acid residues corresponding to L234, L235, D265 and K409 in a human IgG1 heavy chain according to EU numbering are F, E, A and R, respectively, and the second heavy chain comprises a constant region wherein the amino acid residues corresponding to L234, L235, D265 and F405 in a human IgG1 heavy chain according to EU numbering are F, E, A and L, respectively, and
wherein the first light chain and second light chain comprise light chain constant regions comprising the amino acid sequences set forth in SEQ ID NOs: 95 and 96, respectively.

20. The bispecific antibody of claim 19 , which comprises a Fab-arm of a first monoclonal antibody which binds to human 5T4, and a Fab-arm of a second monoclonal antibody which binds to human CD3, wherein the Fab-arm of the first monoclonal antibody comprises the first heavy chain and the first light chain of the bispecific antibody, and wherein the Fab-arm of the second monoclonal antibody comprises the second heavy chain and the second light chain of the bispecific antibody.

21. A composition comprising the antibody of claim 1 and a carrier.

22. A kit comprising the antibody of claim 1 and instructions for use.

Assignees

• Genmab As

Inventors

• Satijn David
• Breij Esther C W
• De Goeij Bart E C G
• Kemper Kristel
• Engelberts Patrick
• Van Den Brink Edward N
• Rademaker Rik
• Verzijl Dennis
• Horbach Sjeng
• Parren Paul

Classifications

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title